To uncover the anti-myofibroblast (MFB) properties of Rhokinase inhibitor (compound Y-27632) and simvastatin in an in vitro model of Peyronie's disease (PD), a sexually debilitating disease caused by an irreversible fibrotic plaque in the penile tunica albuginea (TA).
Materials and Methods
Primary human fibroblasts (FBs) were isolated from surgically obtained TA tissue from patients with PD. To induce MFB status, cells were stimulated with 3 ng/mL transforming growth factor-b1 (TGF-b1). Increasing doses of Y-27632 and simvastatin were added. Real-time quantitative PCR was used to assess mRNA expression of a-smooth muscle actin (a-SMA), collagen III, elastin and connective tissue growth factor (CTGF) after 72 h. Western blot analysis was used to quantify a-SMA protein contents, and immunofluorescence (IF) was used to visualize MFB differentiation by staining for a-SMA after 72 h. A resazurin-based assay was used to assess cell viability to ensure the anti-MFB effect of the drugs. A mechanistic study was performed using IF staining for YAP/ TAZ nuclear translocation.
Results
After 72 h of stimulation with TGF-b1, a six-to 10-fold upregulation of a-SMA could be observed. When treated with Y-27632 or simvastatin, the a-SMA, collagen III, elastin and CTGF mRNA expression was impeded. Additionally, TGF-b1 stimulation showed a twofold increase in a-SMA protein expression, which was reversed to non-stimulated levels after treatment with Y-27632 and simvastatin. Using IF, stimulated cells were identified as MFB (a-SMA+, Vim+) as opposed to the non-stimulated, Y-27632-and simvastatin-treated cells (a-SMAÀ, Vim+). The resazurinbased assay confirmed that the cell viability was not compromised by the administered drugs. On stimulation with TGF-b1, nuclear translocation of YAP/TAZ could be observed, which was prevented by adding the aforementioned compounds.
Introduction
Peyronie's disease (PD) is an acquired fibromatous disorder of the tunica albuginea (TA), causing progressive curvature of the penile shaft. In the initial (acute) phase, it is characterized by erectile pain, without a visible curvature. Within 12-24 months, it evolves into a chronic, painless curvature (or other, e.g. hourglass deformity) of the penis [1] . This deformity of the erect penis is caused by formation of localized contracted fibrotic plaques, which may eventually progress towards calcified or ossified scars [2] . This phenomenon can impair sexual intercourse, cause erectile dysfunction and be the source of significant emotional distress and issues in the relationship [3, 4] .
Contemporary recommended treatment options include surgical correction of the deformity [5] or local injection of Clostridium histolyticum collagenase, into the fibrotic plaques to break them down, correcting the deformities and thereby facilitating sexual intercourse [6] . Long-term results remain relatively unsatisfactory, however, primarily as a result of poor surgical outcomes with penile shortening and new-onset erectile dysfunction, and secondarily because currently available treatment options are merely symptomatic and do not target the underlying pathophysiological processes leading to PD [7] . This lack of effective pharmacological treatments is the consequence of undiscovered molecular mechanisms that lead to the development of PD. The most widely accepted hypothesis dates back to 1997, which postulates that PD is caused by repetitive trauma to the erect penis during intercourse [8] . The mechanical stress during intercourse causes the activation of latent TGF-b1 from the extracellular matrix (ECM) and cells of the innate immunity [9, 10] .
TGF-b1 is a potent inducer of fibrosis as it stimulates the production of pro-fibrotic molecules, such as connective tissue growth factor (CTGF) [11] . Additionally, TGF-b1 incites the transformation of fibroblasts (FBs) into myofibroblasts (MFBs), with subsequent production of ECM [12] . All fibrotic processes have the MFB in common, characterized distinctly by expression of a-smooth muscle actin (a-SMA) [13] . This actin filament is incorporated into stress fibres, which results in increased cell contractility [13] . These steps are the natural processes involved in the wound healing response that can lead to fibrosis if exaggerated or in case of untimely apoptosis of myofibroblasts [14] . Hence, therapeutic strategies need to prevent a phenotypical switch to MFB in order to prevent fibrosis in TA FBs. This means inhibition of a-SMA, CTGF and ECM protein expression needs to be established [15] .
It has been shown that inhibition of Rho-associated coiledcoil forming protein kinase (ROCK) can attenuate TGF-b1 signalling, resulting in impaired production of CTGF and ECM, as well as a decreased rate of FB-to-MFB transformation [16, 17] . ROCK signalling occurs partly through polymerization of G-actin to F-actin and subsequent nuclear translocation of yes-associated protein/transcriptional coactivator with PDZ-binding motif (YAP/TAZ) [18] . The latter binds to the transcription factor transcriptional enhancer factor TEF-1 (TEAD) and M-CAT elements in the nucleus, and drives the expression of several (pro-fibrotic) genes, including CTGF [19] .
Statins are 3-hydroxy-3-methylglutaryl coenzyme-A (HMGCoA) reductase inhibitors that are commonly used for the primary and secondary prevention of cardiovascular morbidities because of their lipid-reducing and direct beneficial cardiovascular effects [20] . In addition to their potency as inhibitors of cholesterol biosynthesis, statins have immuno-modulatory and anti-inflammatory properties [21] . Statins exert their pleiotropic effects independently of their cholesterol-inhibiting properties. Certain intermediates of the cholesterol biosynthesis (farnesyl pyrophosphate and geranylgeranyl pyrophosphate) are also essential for the post-translational modification of the Rho family of proteins [21, 22] ; therefore, statins have the potential to become therapeutic agents for fibrotic diseases through their ROCK-inhibitory effects, among others. The antifibrotic effects of statins have already been investigated in several organ systems, including intestinal, pulmonary, cardiac and renal parenchyma [23] [24] [25] [26] .
In PD, to the best of our knowledge, the antifibrotic effects of ROCK inhibitors and statins have not been tested either in vitro or in vivo. We hypothesized that ROCK inhibitors and statins could serve as repurposed curative treatments for PD in the acute or chronic phase, reducing the need for surgical interventions. In the present study, we investigated the effects and mechanisms of ROCK inhibitors and statins on MFB formation, ECM production and the release of the matricellular protein, CTGF.
Materials and Methods

Patient Samples
Tissue samples from the TA were collected prospectively from patients undergoing surgery for PD (partial plaque excision and grafting; n = 5). Samples were placed in cell culture medium until further processing. This study was approved by the local ethics committee (tracking number s59964).
Fibroblast Isolation from Samples
All samples were dissected with a scalpel, ensuring no residual cavernosal tissue was present. Samples were cut into 3 9 3 mm³ segments and placed onto a Petri dish (10 mm; Corning, Fisher Scientific, Hampton, NH, USA), cell culture medium was added (DMEM/F12, 10% FBS, supplemented with gentamicin and fungizone [Gibco; Thermo-Fisher, Waltham, MA, USA]) and the fragments were left undisturbed for 5 days at 37°C, 5% CO 2, in a humidified atmosphere to ensure FB attachment to the culture well. Once FB growth was established (usually within 5-10 days), tissue fragments were removed, and the medium was changed every 2-3 days. At 80% confluence, cells were split using 0.25% trypsin with EDTA (Gibco; Thermo-Fisher) and reseeded in a T75 (Greiner Bio-One, Kremsmuenster, Austria) flask for further expansion. Passages 2-6 were used for subsequent experiments. Thermo-Fisher), according to the manufacturer's protocol. Real-time PCR was performed using the Taqman â PCR kit (Thermo-Fisher). TaqMan assay primers and probes mix (assays-on-demand TM Gene expression Products) were obtained from (Applied Biosystems; Thermo-Fisher). Reaction mixture (25 lL) containing 1 lL of cDNA template, 1 lL of each primer and probe mix and TaqMan Universal PCR master mix (Applied Biosystems; Thermo-Fisher) amplified as follows: denaturation at 95°C for 10 min and 40 cycles at 95°C for 10 s, 60°C for 20 s. Direct detection of PCR products was monitored by measuring the fluorescence produced by the result of TaqMan probe hydrolysis after every cycle. Cycle times were analysed using the DDC t method. Statistical analysis was performed using GRAPHPAD PRISM (v. 7.0) software. 
Western Blot
Cells were seeded into six-well plates (Corning, Fisher Scientific) at 1.0 9 10 5 cells/well. After overnight incubation, medium was replaced with either fresh medium, medium containing TGF-b1 (3 ng/mL), medium containing TGF-b1 and Y-27632 (1-10-30 lM; Stemcell Technologies) or medium containing TGF-b1 and simvastatin (1.5-5 lM; Sigma-Aldrich) for 72 h. Cell pellet was obtained by removing cells from the six-well plates using trypsin and centrifugation at 1000 g for 5 min.
Protein concentration was determined by the BCA Protein Assay (Pierce; Thermo-Fisher). Then, 30 lg of protein was loaded onto an SDS-PAGE gel (Any kD Mini-Protean TGX; Bio-Rad, Hercules, CA, USA) and transferred to a PVDF membrane (Thermo-Fisher). After 1-h blocking in 10% non-fat dried milk, the membrane was incubated with primary antibodies (rabbit polyclonal anti-a-SMA (ab5694, 1:500; Abcam, Cambridge, UK) and mouse monoclonal anti-GAPDH (ab8245, 1:10000; Abcam) at 4°C overnight, then washed with TBS+0.1% Tween 20, and probed with secondary antibodies (goat anti-rabbit/anti-mouse secondary antibody conjugated with HRP [ab205718/ab205719, 1:5000; Abcam]), diluted in 5% non-fat dried milk and TBS. Protein-antibody complexes were detected by G:BOX Chemi XRQ (Syngene; VWR, Radnor, PA, USA). Quantitation of the signal was performed using IMAGEJ software. Statistical analysis was performed using GRAPHPAD PRISM (v7.0) software.
Immunocytochemistry
The cells were seeded into a 12-well plate (Corning, Fisher Scientific) containing sterilized glass coverslips at 5.0 9 10 4 cells/well. After overnight incubation, the medium was replaced with either fresh medium, medium containing TGFb1 (3 ng/mL), medium containing TGF-b1 and Y-27632 (30 lM; Stemcell Technologies) or medium containing TGFb1 and simvastatin (1.5 lM; Sigma-Aldrich) for 72 h.
Coverslips carrying the cells were washed in PBS and fixed using 4% paraformaldehyde and 100% ethanol. Coverslips were incubated with 10% natural goat serum (Dako, Heverlee, Belgium) in TBS for 1 h and further overnight with rabbit polyclonal antia-SMA antibody (ab5964, 1:200; Abcam), mouse monoclonal anti-vimentin antibody (ab8789, 1:500; Abcam) and mouse monoclonal anti-YAP/TAZ (sc-101199, 1:50; Santa Cruz, Dallas, TX, USA). Slides were incubated for 1 h with goat anti-rabbit secondary antibody conjugated with fluorescein dye (ab150077, 1:250; Abcam) and goat anti-mouse secondary antibody conjugated with fluorescein dye (ab150116, 1:250; Abcam). Slides were then viewed and imaged using a Nikon Eclipse C1 microscope with NIS elements (Version 4.60) imaging software.
Results
TGF-b1 Induces a Myofibroblast Phenotype in Human primary Fibroblasts and Induces Chemokine and Extracellular Matrix Production
To show a homogenous PD-derived FB cell population devoid of smooth muscle cells and/or MFBs, real-time quantitative (Fig. 1A) . Stainings for vimentin and a-SMA using IF showed that unstimulated cells are positive for vimentin (Vim+) and negative for a-SMA (a-SMAÀ [Fig. 1B] ). On TGF-b1 stimulation, there was a significant increase in mRNA levels of a-SMA, CTGF, collagen I, collagen III and elastin ( Fig. 2A) . Protein levels of a-SMA were assessed using Western blot and IF (Fig. 2B-C) . On TGF-b1 stimulation, the PD-derived FBs became Vim+ and a-SMA+, suggesting their transformation into MFBs.
Rho-kinase Inhibitor Y-27632 Inhibits Myofibroblast Transformation, Connective Tissue Growth Factor and Extracellular Matrix Production
To investigate the effects of Rho-kinase inhibition on TGFb1-induced MFB transformation and production of ECM and CTGF, we co-incubated FBs with TGF-b1 3 ng/mL and increasing doses of the ROCK inhibitor Y-27632. We assessed the effect of Y-27632 on cell viability and proliferation using a resazurin-based assay (Alamar Blue). Figure 3A shows that Y-27632 affected neither cell viability nor the rate of proliferation. Figure 3B shows there is no significant difference in caspase-3 mRNA levels, further suggesting the lack of apoptosis induction by Y-27632.
After 72 h of stimulation with TGF-b1, a-SMA was upregulated six-to 10-fold in stimulated cells compared with non-stimulated ones ( Fig. 2A) . Incubation with Y-27632 reduced a-SMA mRNA expression by approximately half at the maximum concentration of 30 lM. We observed a similar pattern in mRNA levels of CTGF and collagen III (Fig. 4A) . Seventy-two-hour incubation with TGF-b1 resulted in a twofold increase in a-SMA protein expression on Western blot, which was reversed to nonstimulated levels after treatment with Y-27632 (30 lM) (Fig. 4B) nonsignificant levels of caspase-3 mRNA expression between unstimulated, stimulated and simvastatin treatment. Error bars represent SEM. P value was considered significant if <0.05. T0 = TGF-b1 0 ng/mL; T3 = TGF-b1 3 ng/mL; T3 + S0.5 = TGF-b1 3 ng/mL + Simvastatin 0.5 lM; T3 + S1.5 = TGF-b1 3 ng/mL + Simvastatin 1.5 lM; T3 + S5 = TGF-b1 3 ng/mL + Simvastatin 5 lM; T3 + S15 = TGF-b1 3 ng/mL + Simvastatin 15 lM; T3 + V = TGF-b1 3 ng/mL + Vehicle. were exposed to TGF-b1 (3 ng/mL; middle), YAP/TAZ was translocated to the nucleus. When treating these stimulated cells with simvastatin 1.5 lM (right), nuclear staining of YAP/TAZ returned to pre-stimulation levels (nuclear stain DAPI). T0 = TGF-b1 0 ng/mL; T3 = TGF-b1 3 ng/mL; T3 + S0.5 = TGF-b1 3 ng/mL + Simvastatin 0.5 lM; T3 + S1.5 = TGF-b1 3 ng/mL + Simvastatin 1.5 lM; T3 + S5 = TGF-b1 3 ng/mL + Simvastatin 5 lM; T3 + S15 = TGF-b1 3 ng/mL 
Simvastatin Inhibits Myofibroblast Transformation, Chemokine and Extracellular Matrix Production
To investigate the effects of simvastatin on TGF-b1-induced MFB transformation and production of ECM and CTGF, FBs were incubated with TGF-b1 and increasing doses of simvastatin.
First, the effect of simvastatin on cell viability and proliferation was assessed using a resazurin-based assay (Alamar Blue). Figure 5A shows that simvastatin did not affect cell viability, but cells treated with simvastatin had a significantly slower growth rate. Figure 5B shows equal caspase-3 levels between all treatment groups.
When TGF-b1-stimulated cells were treated with simvastatin, the a-SMA mRNA levels were decreased to pre-treatment levels. Similar observations could be made for mRNA expression of CTGF, elastin, collagen I and collagen III (Fig. 6A) . A reversal to non-stimulated levels of a-SMA protein expression after treatment with simvastatin was detected as well (Fig. 6B) . Using IF, stimulated cells were identified as MFB (a-SMA+, Vim+) as opposed to the non-stimulated and simvastatin-treated cells (a-SMAÀ, Vim+ [ Fig. 6C] ).
After treatment with simvastatin, the prevention of nuclear translocation of YAP/TAZ could be observed, suggesting that simvastatin might work through a similar pathway to ROCK inhibition (Fig. 6D) .
Discussion
Even though the use of ROCK inhibitors and simvastatin has been described in other fibrotic diseases [23] [24] [25] [26] , these compounds remain uninvestigated in PD. This study explores the possible therapeutic potential of these compounds for the treatment of early-or late-phase PD. First, we characterized the cells isolated from PD plaques. Unstimulated, harvested cells were stained positive for vimentin and negative for a-SMA, while desmin mRNA levels were nearly undetectable. Stimulation of the cells with TGFb1 caused a significant increase in a-SMA expression on mRNA and protein level, suggesting an MFB phenotype [27] . Furthermore, we also observed an increased level of ECM (collagen I, III and elastin) and CTGF mRNA production. This is the first report that suggests an upregulation of CTGF in TGF-b1-stimulated PD-derived FBs.
The role of MFBs in fibrosis has been well established for over a decade [28] . In physiological wound healing, they are responsible for wound contraction, production of ECM and several chemokines. Their delayed apoptosis can lead to persisting fibrogenesis and, ultimately, fibrosis. The main signature of MFB is their co-expression of vimentin and a-SMA, the latter being a marker that also occurs in smooth muscle cells (which are negative for vimentin) [29] . Thus, inhibition of expression of a-SMA can be used to study the rate of MFB differentiation.
During inflammation and wound healing, MFBs are formed from a diverse set of cell types. The initial trigger for MFB formation can differ depending on its origin. For example, MFBs can develop from epithelial/endothelial-tomesenchymal transition by TGF-b1, IGF-1, EGF and FGF2 [30, 31] . Other sources are circulating bone marrow-derived fibrocytes which are activated by TGF-b1 and endothelin-1 [31, 32] . Tissue-resident FBs undergo a transformation into MFBs through TGF-b1 (released from inflammatory macrophages and the ECM), interleukin-1b, platelet-derived growth factor and reactive oxygen species [31, 33] . In PD, the origin of MFBs is ill-investigated; nonetheless, it seems that TGF-b1 is the common denominator. Thus, inhibition of TGF-b1 signalling would probably impair MFB formation and subsequent fibrosis, regardless of the MFB origin, especially because TGF-b1 has been previously described as a main driver of MFB transformation in PD [9, 34, 35] , to the extent that the most widely used animal model of the disease is based on injection of the cytokine [10, 35, 36] .
In the present series of experiments, we found that Y-27632 could significantly impede TGF-b1-induced MFB transformation, as evidenced on an mRNA and protein level, while there was also a significantly reduced expression of CTGF and collagen III. These data suggest that ROCK inhibitors can inhibit the formation of MFBs, and hence inhibit their secretory capabilities. Interestingly, ROCK inhibitors have also been shown to improve smooth muscle cell relaxation in human corpus cavernosum [4, 37] . Considering that most patients with PD also have erectile dysfunction [5] , therapy with ROCK inhibitors could not only lead to attenuated fibrosis, but also improvement of erectile function. In the canonical pathway, TGF-b1 signalling occurs via phosphorylation and nuclear translocation of SMAD proteins [38, 39] . Additionally, TGF-b1 has been shown to induce MFB transformation by acting on the ROCK signalling axis. Mechanistically, in the present study, we suggest that TGF-b1 signalling in TA-derived FBs occurs through ROCK-mediated YAP/TAZ nuclear translocation. This nuclear activity of YAP/TAZ leads to transcription of several pro-fibrotic genes, including collagens and CTGF [19] , and further investigation of this pathway may lead to novel treatment targets.
Statins have been used for decades in the treatment of atherosclerosis and secondary prevention of cardiovascular disease [20] ; however, a role for them in PD-related fibrosis has never been reported. Our findings could suggest that active plasma levels of simvastatin could be beneficial for inhibition of FB to MFB transformation and thus impeded fibrogenesis in a clinical setting. We show in our experiments that simvastatin is a very potent inhibitor of MFB transformation, production of ECM (collagen I, III and elastin) and CTGF mRNA. Additionally, the proliferation of PD-derived FBs was attenuated in comparison with controls or TGF-b1-stimulated cells. As has been described earlier, simvastatin exerts its effect partly through inhibition of the ROCK pathway, as evidenced by the inhibition of the nuclear translocation of YAP/TAZ [25, 39, 40] .
Although more mechanistic studies need to be performed to demonstrate the exact mechanisms of action of ROCK inhibitors and simvastatin, the present study shows for the first time that they could be beneficial in curbing early fibrogenesis and plaque development in patients with PD. We also showed for the first time that TGF-b1 stimulation of TA-derived FBs leads to a significant upregulation of CTGF mRNA expression. Additionally, this increase could be attenuated (Y-27632) or prevented completely (simvastatin). Upregulation of CTGF has already been described in fibrotic diseases of the lung, liver and kidney, amongst others [41] . CTGF, as a matricellular protein, exerts its fibrotic effects through several mechanisms: binding to cell surface receptors and initiating signal transductions, binding to cytokines and mediating their binding to specific receptors, remodelling the ECM turnover and regulating the activity of cytokines and growth factors through signalling crosstalks [42] . Our data suggest that YAP/TAZ nuclear translocation, at least partially, drives CTGF activation. YAP/TAZ has been shown to be an effective CTGF stimulator in kidney and corneal epithelial cells and endothelial cells, to mention a few [43] [44] [45] .
Inhibiting CTGF with direct pharmacological interventions might offer additional treatment options for PD. The CTGF monoclonal antibody FG-3019/pamrevlumab, for instance, has been demonstrated to be well tolerated and effective in a phase II clinical trial of idiopathic pulmonary fibrosis and is © 2018 The Authors BJU International © 2018 BJU International 713 currently being tested for muscular dystrophy and pancreatic cancer in clinical trials [46] .
Further experiments assessing the precise downstream effectors (other than ROCK signalling) need to be performed to elucidate the mechanism of action of simvastatin in PDderived FBs. Additionally, to translate this into a clinical setting, in vivo studies using statins in a PD animal model need to be carried out. Nonetheless, Y-27632 and simvastatin show considerable potential in the search for much-needed, novel therapeutics in PD.
In conclusion, using patient TA FBs derived from patients with PD, we set up an in vitro model of PD using TGF-b1 stimulation. We were able to show the anti-MFB and anti-ECM-producing properties of Y-27632 and simvastatin in this in vitro setting. Both ROCK inhibition and HMG-coA reductase inhibitors could provide fascinating new outlooks on the medical treatment of PD in the near future.
